Zacks Investment Research upgraded shares of TherapeuticsMD (NASDAQ:TXMD) from a sell rating to a hold rating in a report issued on Saturday.

According to Zacks, “TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida. “

A number of other analysts have also recently commented on TXMD. Jefferies Group reiterated a buy rating and set a $15.00 target price on shares of TherapeuticsMD in a research report on Tuesday, September 26th. BidaskClub cut TherapeuticsMD from a hold rating to a sell rating in a research report on Wednesday, September 27th. Oppenheimer set a $10.00 target price on TherapeuticsMD and gave the stock a buy rating in a research report on Monday, October 16th. Cowen reiterated an outperform rating and set a $16.00 target price (up previously from $13.00) on shares of TherapeuticsMD in a research report on Monday, November 6th. Finally, Cantor Fitzgerald reiterated a buy rating and set a $31.00 target price on shares of TherapeuticsMD in a research report on Wednesday, November 29th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the company. The stock has a consensus rating of Buy and a consensus price target of $14.50.

Shares of TherapeuticsMD (NASDAQ TXMD) opened at $6.45 on Friday. TherapeuticsMD has a 52-week low of $3.50 and a 52-week high of $8.30. The company has a market capitalization of $1,400.00, a PE ratio of -16.54 and a beta of 1.06.

TherapeuticsMD (NASDAQ:TXMD) last posted its earnings results on Monday, November 6th. The company reported ($0.07) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.10) by $0.03. TherapeuticsMD had a negative return on equity of 65.16% and a negative net margin of 457.00%. The business had revenue of $4.42 million for the quarter, compared to analysts’ expectations of $5.36 million. During the same quarter in the previous year, the firm earned ($0.13) earnings per share. The business’s revenue was down 19.7% compared to the same quarter last year. research analysts expect that TherapeuticsMD will post -0.37 earnings per share for the current fiscal year.

In related news, Director Tommy G. Thompson purchased 5,000 shares of the company’s stock in a transaction that occurred on Friday, December 8th. The shares were purchased at an average price of $6.21 per share, for a total transaction of $31,050.00. Following the transaction, the director now directly owns 3,555 shares of the company’s stock, valued at approximately $22,076.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 23.92% of the company’s stock.

A number of hedge funds have recently modified their holdings of TXMD. Amalgamated Bank increased its position in TherapeuticsMD by 7.2% in the 2nd quarter. Amalgamated Bank now owns 19,744 shares of the company’s stock valued at $104,000 after acquiring an additional 1,322 shares during the period. Principal Financial Group Inc. increased its position in TherapeuticsMD by 3.9% in the 2nd quarter. Principal Financial Group Inc. now owns 21,711 shares of the company’s stock valued at $114,000 after acquiring an additional 818 shares during the period. Edge Wealth Management LLC increased its position in TherapeuticsMD by 2,500.0% in the 4th quarter. Edge Wealth Management LLC now owns 20,800 shares of the company’s stock valued at $125,000 after acquiring an additional 20,000 shares during the period. Virtu KCG Holdings LLC acquired a new position in TherapeuticsMD in the 2nd quarter valued at about $157,000. Finally, Quantbot Technologies LP acquired a new position in TherapeuticsMD in the 3rd quarter valued at about $189,000. Hedge funds and other institutional investors own 73.78% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Zacks Investment Research Upgrades TherapeuticsMD (TXMD) to Hold” was first published by Daily Political and is the property of of Daily Political. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.dailypolitical.com/2018/01/23/zacks-investment-research-upgrades-therapeuticsmd-txmd-to-hold.html.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Get a free copy of the Zacks research report on TherapeuticsMD (TXMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.